Artificial Intelligence
Global Vision Guided Robotics Market Forecast 2020-2027: COVID-19 Impact and Analysis by Component Type, Type, and Industry Vertical
Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) — The “Vision Guided Robotics Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Component Type, Type, and Industry Vertical” report has been added to ResearchAndMarkets.com’s offering.
Rapid Expansion among Industrial Application in Asia Pacific to Lead Vision Guided Robotics Market Growth
The market was valued at US$ 4,616.6 million in 2019 and is projected to reach US$ 12,958.9 million by 2027; it is expected to grow at a CAGR of 13.8% during the forecast period.
Advancement of camera technologies and processing power are enabling robots to take on more amorphous tasks such as driving, flying, and mobile activities, among others, which requires obstacle identification and avoidance capabilities through vision systems. The major areas for robot manufacturers to develop a robust vision-guided robot include fast increasing computing power, advancement in imaging hardware, improvement in high-level software libraries, and reducing the cost of computer memory. Also, the advancement of machine vision will bolster the automation technology in the industrial sector in the coming years.
The vision guided robotics market report has been derived from market trends and revenue generation factors from five different regions across the globe: North America, Europe, Asia Pacific, Middle East & Africa, and South America. APAC is expected to be the fastest growing region in the global vision guided robotics market during the forecast period. Whereas, APAC was followed by Europe and North America hold the highest market share in the vision guided robotics market. The vision guided robotics market is expected to experience significant growth in the coming years due to increasing demand for automation.
The market for vision-guided robotics is highly fragmented, and the industry is constantly experiencing the emergence of a new player with innovative technologies. With an objective to sustain in the industry and compete with its peers, the companies are adopting several organic and inorganic strategies which include competitive pricing, miniaturized camera sensors, mergers and acquisition, and additional aftersales service.
These strategies offer the companies a significant competitive edge over the others. The vision-guided robotics market is poised to flourish in the coming years owing to the fact that, several developing country governments are attracting foreign direct investments (FDI) to optimize hectic and monotonous operations performed across industries with ease and precision. Additionally, the demand for 3D vision technology is growing at a rapid rate among the end users, which is compelling the manufacturers to innovate and develop robust software and hardware for robotic systems.
Major players operating in the vision guided robotics market include ABB Ltd., Fanuc Corporation, Basler AG, Cognex, ISRA Vision, Yaskawa Electric Corporation, Universal Robots AS, Denso Corporation, and Omron Corporation.
COVID-19 Impact on Vision Guided Robotics Market
As of August 2020, the US, India, Russia, Spain, Germany, China, France, Iran, and the UK are some of the worst affected countries in terms of confirmed cases and reported deaths. In the wake of strong lockdown regulations imposed by the majority of the countries across the globe, the automotive and electronics sector is experiencing a significantly lower demand in respective regions.
The North America region, especially the U.S., witnessed an unprecedented rise in number of confirmed cases resulting in large-scale lockdown across different regions. Moreover, the manufacturers and brands are facing various short-term challenges regarding maintaining the supply chain activities through retailers, distributors, and suppliers of vision guided robotics across the North American countries.
Countries such as the US and Canada limited the production of automobiles and electronics owing to the outbreak of virus. However, ease of lockdown restrictions along with emphasis toward effective restoration of automotive industry related supply chain operations has mitigated the negative influence of the COVID over the market growth.
Key Topics Covered:
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
2. Key Takeaways
3. Research Methodology
4. Vision Guided Robotics Market Landscape
4.1 Market Overview
4.2 Ecosystem Analysis
4.3 PEST Analysis
5. Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Government Support for the Development and Deployment of Robotics
5.1.2 Rise in aging population worldwide resulting in labour shortage
5.1.3 Rapid Expansion in Manufacturing Industry
5.1.4 Rapid Expansion in Industrial Application
5.2 Key Market Restraints
5.2.1 High capital required for initial deployment of vision guided vision guided robots
5.3 Key Market Opportunity
5.3.1 Widespread Adoption of Industrial Automation in Diverse Industries
5.4 Future Trends
5.4.1 Integration of Artificial Intelligence and Big Data
5.5 Impact Analysis of Drivers and Restraints
6. Vision Guided Robotics – Global Market Analysis
6.1 Global Vision Guided Robotics Market Overview
6.2 Global Vision Guided Robotics Market Forecast and Analysis
6.3 Market Positioning
7. Vision Guided Robotics Market Revenue and Forecasts to 2027- Component
7.1 Overview
7.2 Global Vision Guided Robotics Market Breakdown, By Component, 2018 & 2027
7.3 Hardware Market
7.3.1 Overview
7.3.2 Hardware Market Forecast and Analysis
7.4 Software Market
7.5 Services Market
8. Vision Guided Robotics Market Revenue and Forecasts to 2027-Type
8.1 Overview
8.2 Global Vision Guided Robotics Market Breakdown, By Type, 2018 & 2027
8.3 2D-Vision System Robots
8.3.1 Overview
8.3.2 2D-Vision System Robots Market Forecast and Analysis
8.4 3D-Vision System Robots Market
9. Vision Guided Robotics Market Revenue and Forecasts to 2027-Industry Vertical
9.1 Overview
9.2 Global Vision Guided Robotics Market Breakdown, By Industry Vertical, 2018 & 2027
9.3 Automotive Market
9.3.1 Overview
9.3.2 Automotive Market Forecast and Analysis
9.3.3 Global Vision Guided Robotics Market, by Automotive – Revenue and Forecast to 2027 (USD Million)
9.4 Electrical & Electronics Market
9.5 Aerospace & Defence Market
9.6 Food & Beverages Market
9.7 Healthcare & Pharmaceutical Market
9.8 Metal Processing Market
10. Vision Guided Robotics Market – Geographical Analysis
11. Impact of Coronavirus Outbreak
11.1 Impact of COVID-19 Pandemic On Global Vision guided robotics Market
11.1.1 North America: Impact Assessment of COVID-19 Pandemic
11.1.2 Europe: Impact Assessment of COVID-19 Pandemic
11.1.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.1.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
11.1.5 South America: Impact Assessment of COVID-19 Pandemic
12. Vision Guided Robotics Market – Industry Landscape
12.1 Market Initiative
12.2 Merger and Acquisition
12.3 New Development
13. Key Players
13.1 Key Facts
13.2 Business Description
13.3 Products and Services
13.4 Financial Overview
13.5 SWOT Analysis
13.6 Key Developments
- ABB Ltd.
- Basler AG
- Cognex
- Denso Corporation
- Fanuc Corporation
- ISRA Vision
- Omron Corporation
- Pleora Technologies Inc
- Universal Robots AS
- Yaskawa Electric Corporation.
For more information about this report visit https://www.researchandmarkets.com/r/c50t2p
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
SciBase publishes prospectus in connection with upcoming rights issue
STOCKHOLM, April 19, 2024 /PRNewswire/ — On 5 April 2024, SciBase Holding AB (publ) (“SciBase” or the “Company”) announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units, consisting of new shares and warrants of series TO 2, of approximately SEK 15 million (the “Rights Issue). Today, SciBase announces that the prospectus relating to the Rights Issue (the “Prospectus”) has been approved by the Swedish Financial Supervisory Authority (the “SFSA”) and has been made available on the Company’s webpage, https://investors.scibase.se/en/share/prospectus-regarding-shares, together with other information related to the Rights Issue. The Prospectus will also be made available on Vator Securities’ webpage, www.vatorsecurities.se , and at the SFAS’s webpage, www.fi.se.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Timetable for the Rights Issue
19 April 2024
Record date to receive unit rights
23 April 2024 – 2 May 2024
Trading in unit rights
23 April 2024 – 7 May 2024
Subscription period
23 April 2024 – 27 May 2024
Trading in BTU
Around 10 May 2024
Announcement of the outcome of the Rights Issue
3 April 2029 – 17 April 2029
Subscription period for warrants of series TO 2
Advisors
Vator Securities is the financial advisor and Advokatfirman Schjødt is the legal advisor to SciBase in connection with the Rights Issue.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA)Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The Company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of units in SciBase in the Rights Issue should only be made on the basis of the information contained in the formal prospectus issued in connection with the Rights Issue, which was approved by the Swedish Financial Supervisory Authority on 19 April 2024.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”) and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue,c3964524
The following files are available for download:
https://mb.cision.com/Main/12371/3964524/2745667.pdf
Publishing of prospectus SciBase
View original content:https://www.prnewswire.co.uk/news-releases/scibase-publishes-prospectus-in-connection-with-upcoming-rights-issue-302122089.html
Artificial Intelligence
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 18, 2024 /PRNewswire/ — The report titled “Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $342.20 million in 2023 to reach $832.56 million by 2030, at a CAGR of 13.54% over the forecast period.
“The Global Surge in Adoption of Matching Software for Enhanced Participant Enrollment”
Clinical trials matching software stands at the forefront of revolutionizing clinical research by automating the process of identifying and enrolling eligible participants. These platforms offer a streamlined approach to match patient health profiles with trial requirements, accelerating enrollment and supporting the shift toward personalized healthcare using these advanced AI and ML technologies. Although integrating these systems poses challenges due to variations in healthcare IT infrastructure and the imperative for rigorous data security, the potential for market growth is substantial. In the Americas, a robust clinical trials ecosystem thrives; in the European Union, it has unified regulatory standards and extended to emerging regions such as the Middle East, Africa, and the APAC countries; the demand for such innovative solutions is on a steep rise. This demand is fueled by governmental support, the evolving regulatory landscape, and strategic partnerships to embed these solutions within electronic health records, underscoring a global movement toward optimizing clinical trial processes to better cater to specific patient demographics.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“The Rise of Virtual Trials and Advanced Matching Software”
The healthcare landscape is witnessing a transformative shift toward virtual clinical trials, fueled by technological advancements and the necessity for continuity during the COVID-19 pandemic. This transition supports research amid social distancing measures and introduces significant cost savings by reducing the need for physical infrastructure and in-person interactions. The efficiencies brought by electronic health records (EHR), wearable technologies, and automation streamline the entire process, from patient recruitment to data analysis. Several approaches, endorsed by regulatory bodies such as the FDA, represent a leap forward in making clinical trials more accessible and streamlined, ensuring that more patients can participate in potentially life-saving research without the geographical and logistic constraints of traditional trials.
“Enhancing Clinical Trials through Advanced Analytics, Rigorous Compliance, and Precision-Patient Matching”
Integrating advanced analytics, meticulous compliance monitoring, and precision-patient matching marks a significant advancement toward maximizing efficiency and fostering trial diversity. The software delivers insightful data on trial progress, participant demographics, and enrollment figures, empowering stakeholders to make well-informed decisions and optimize resource distribution to meet trial goals effectively by implementing cutting-edge analytics. The built-in compliance feature ensures trials are conducted in strict adherence to regulatory standards, minimizing risks associated with non-compliance. Furthermore, a robust data management system guarantees the integrity and availability of clinical trial data, which is critical for the seamless operation and real-time analysis of trials. The software includes state-of-the-art patient matching technology, which employs sophisticated algorithms and artificial intelligence to expedite recruitment by accurately identifying candidates who match specific trial requirements. This innovative approach accelerates the recruitment timeline and enhances the diversification of trial participants, paving the way for more inclusive and representative clinical research outcomes.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Medidata by Dassault Systèmes SE at the Forefront of Clinical Trials Matching Software Market with a Strong 11.30% Market Share”
The key players in the Clinical Trials Matching Software Market include International Business Machines Corporation, Science 37, Inc. by eMed, LLC, Medidata by Dassault Systèmes SE, AutoCruitment LLC, Deep 6 AI Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trials Matching Software Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trials Matching Software Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trials Matching Software Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Dive into the Clinical Trials Matching Software Market Landscape: Explore 190 Pages of Insights, 286 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trials Matching Software Market, by FunctionalityClinical Trials Matching Software Market, by DeploymentClinical Trials Matching Software Market, by End-UseAmericas Clinical Trials Matching Software MarketAsia-Pacific Clinical Trials Matching Software MarketEurope, Middle East & Africa Clinical Trials Matching Software MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030Virtual Clinical Trials Market – Global Forecast 2024-2030Clinical Trials Management System Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo – https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-matching-software-market-projected-to-reach-832-56-million-by-2030—exclusive-report-by-360iresearch-302119709.html
Artificial Intelligence
RepTrak Announces 2024 Global RepTrak® 100 Report
BOSTON, April 18, 2024 /PRNewswire/ — The RepTrak™ Company, the world’s leading reputation data and insights company, released its annual Global RepTrak 100 report. Utilizing its advanced reputation monitoring software, RepTrak gathered data from more than 243,000 survey responses across 14 major economies to rank the world’s 100 most reputable companies. They share that ranking alongside a full analysis of global corporate reputation trends and corresponding public sentiment in the 2024 report.
After two years of consecutive Reputation Score declines, this year’s Score is back up with an increase from 73.2 in 2023 to 73.8 in 2024. It’s a small increase after 2023’s full one-point drop. However, it’s an encouraging sign that companies have begun to recover from reputation falls driven by many challenges: macroeconomic issues, workplace difficulties, product problems, and corporate responsibility skepticism.
“This year’s report underscores a pivotal shift in the corporate landscape, spotlighting the remarkable adaptability and dedication of the Top 100 companies in responding to the dynamic needs of stakeholders,” states RepTrak CEO Mark Sonders. “The companies featured in our report are not just riding the wave of change; they are the ones steering it, proving that the best approach to business is one that embraces evolution and champions progress.”
RepTrak’s report explores how people thought, felt, and acted toward companies over the past year. Findings include notable increases in Conduct and Citizenship efforts, stakeholders’ rising willingness to invest, culturally resonant brand communications, and ESG Scores that soared despite skepticism around the acronym.
To read the full 2024 Global RepTrak 100 report, please visit: www.reptrak.com/globalreptrak
About RepTrak
The RepTrak™ Company is the world’s leading reputation data and insights company. We help companies by organizing and grading a variety of reputational elements, offering a real-world report card on their corporate reputation. Subscribers to the RepTrak program use our predictive insights to protect business value, improve return on investment, and increase their positive impact on society. RepTrak’s pairing of advanced metrics and dedicated reputation advisors offers clients an actionable analysis of their reputation data, aligning business objectives with stakeholder sentiment across different markets and sectors.
Established in 2004, The RepTrak Company owns the world’s largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit: www.reptrak.com
Logo – https://mma.prnewswire.com/media/2391550/RepTrak_Logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2391551/2024_GRT_Spreads__Instagram_Post.jpg
View original content:https://www.prnewswire.co.uk/news-releases/reptrak-announces-2024-global-reptrak-100-report-302121513.html
-
Artificial Intelligence7 days ago
In-Depth Analysis of Germany and France Data Center Markets: Germany Poised to Contribute Over $12.24 Billion Opportunities in the Next 6 Years – Arizton
-
Artificial Intelligence7 days ago
CogX Festival Set to Debut in Los Angeles at Century Plaza on May 7th, 2024
-
Artificial Intelligence5 days ago
Silent Eight secures AIA as its latest client
-
Artificial Intelligence4 days ago
Global Networking Innovator Huawei Leads the New Era of Campus Network Technology
-
Artificial Intelligence2 days ago
Huawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Artificial Intelligence4 days ago
Broadcom Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Delivering Reliable and Flexible Hybrid Cloud Management Solutions
-
Uncategorized4 days ago
Google Cloud Dominates GCN Conference With Artificial Intelligence News
-
Artificial Intelligence3 days ago
vLex Launches Vastly Expanded Vincent Legal GenAI Toolset, and AI-Focused Co-Development Lab